Cirena provides custom-synthesized RNA oligonucleotides up to 300 nucleotides in length, with site-specific modifications and high purity. They enable researchers in biotech and pharma to accelerate the development of novel RNA-based therapeutics and technologies by delivering scalable quantities from micrograms to grams.
Funding
Funding not disclosed
Founders
Product
Problem
The development of advanced RNA-based therapeutics and technologies is hindered by limitations in accessing high-purity, chemically synthesized RNA with precise modifications. This bottleneck restricts the pace of innovation in nucleic acid research and development.
Solution
Cirena offers chemically synthesized RNA oligonucleotides up to 300 nucleotides in length, available in microgram to gram quantities. The company specializes in providing site-specific modifications, enabling researchers to design and develop novel RNA-based therapeutics and technologies. By delivering high-purity RNA constructs, Cirena acts as a key enabler for advancements in nucleic acid technologies, making complex synthesis accessible for next-generation applications.
Target Audience
Cirena serves researchers and developers in the biotechnology and pharmaceutical sectors focused on nucleic acid-based therapeutics and advanced RNA technologies.
Features
- Chemical synthesis of RNA oligonucleotides up to 300 nucleotides in length.
- Production scalability from microgram to gram quantities.
- Capability for site-specific chemical modifications on RNA strands.
- High-purity synthesis to ensure reliable experimental outcomes.